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ABSTRACT
The pharmacokinetics and pharmacodynamics of the two main
metabolites of tramadol, (1)-O-desmethyltramadol and (2)-O-
desmethyltramadol, were studied in rats. Pharmacodynamic
endpoints evaluated were respiratory depression, measured as
the change in arterial blood pCO2, pO2, and pH levels; and
antinociception, measured by the tail-flick technique. The ad-
ministration of 10 mg/kg (1)-O-desmethyltramadol in a 10-min
i.v. infusion significantly altered pCO2, pO2, and pH values in
comparison with baseline and lower-dose groups (P , .05).
However, 2 mg/kg administered in a 10-min i.v. infusion was
enough to achieve 100% antinociception without respiratory
depression. Moreover, the b-funaltrexamine pretreatment com-
pletely eliminated the antinociception of the 2-mg/kg dose,
suggesting that such an effect is due to m-opioid receptor
activation. To describe and adequately characterize the in vivo
antinociceptive effect of the drug, (1)-O-desmethyltramadol
was given at different infusion rates of varying lengths (10–300
min). Pharmacokinetics was best described by a two-compart-
mental model. The time course of response was described
using an effect compartment associated with a linear pharma-
codynamic model. The estimates of the slope of the effect
versus concentration relationship were significantly decreased
(P , .05) as the length of infusion was increased, suggesting
the development of tolerance. Doses of up to 8 mg/kg (2)-O-
desmethyltramadol given in 10-min i.v. infusion did not elicit
either antinociception in the tail-flick test or respiratory effects.
These in vivo results are in accordance with the opiate and
nonopiate properties reported for these compounds in several
in vitro studies.
Tramadol hydrochloride is a centrally acting analgesic
drug that is widely used in the treatment of pain. It exhibits
good analgesic efficacy and a potency comparable to codeine
(Hummel et al., 1996; Miranda and Pinardi, 1998).
Tramadol is administered as a racemic mixture of two
enantiomers, (1)-tramadol and (2)-tramadol, that are essen-
tially metabolized by the liver (Lee et al., 1993), producing
mainly the (1)-O-desmethyltramadol, (1)-M1, and (2)-O-
desmethyltramadol, (2)-M1, metabolites, respectively. There
is evidence that the M1 enantiomers show analgesic activity
in mice and rats (Hennies et al., 1988). The fact that these
four compounds [(1)- and (2)-tramadol and (1)- and (2)-M1]
have different pharmacological properties (Raffa and Fri-
derichs, 1996) makes tramadol an atypical opioid with a
complex mechanism of action.
Although the opioid component of tramadol-induced an-
tinociception was detected in early preclinical in vitro and in
vivo studies, the importance of the nonopioid component has
been recognized by Raffa et al. (1992). Frink et al. (1996)
have demonstrated in in vitro receptor binding and synapto-
somal uptake experiments that the (1)-enantiomers are
bound mainly to the opioid receptor, (1)-M1 being the com-
pound with the highest affinity for the m-receptors; on the
other hand, (2)-enantiomers had the ability to inhibit the
noradrenaline (NA) uptake. Additionally, (1)-tramadol had
the property of inhibiting serotonin uptake. These results
have also been supported by other authors, such as Driessen
et al. (1993), Sevcik et al. (1993), Lai et al. (1996), and
Bamigbade et al. (1997).
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Although several in vivo studies (Raffa et al., 1992, 1993)
dealing with the role of the opioid and nonopioid components
in analgesia induced by tramadol corroborate the in vitro
findings (Raffa et al., 1995), there is little or no information
regarding the pharmacokinetic (pk) properties of the tram-
adol enantiomers and their metabolites or their pharmacoki-
netic/pharmacodynamic (pk/pd) relationships. pk/pd studies
have been used as a tool for describing and predicting the
time course of the in vivo effect in different scenarios (Der-
endorf and Hochhaus, 1995). In the case of tramadol, the
following pk and pd complexities could hamper a priori the
interpretation of the time course of its effect: 1) transport to
the biophase (central nervous system), 2) active metabolites,
3) pd interactions among the enantiomers and metabolites,
and 4) eventual development of tolerance. For all of these
reasons, in this study we approach the understanding of the
in vivo effect of tramadol by characterizing first the relation-
ship between the pk and the antinociceptive effects of its
metabolites, (1)-M1 and (2)-M1. In addition, the irreversible
m-antagonist b-funaltrexamine (b-FNA) was administered to
explore the role of m-receptor in the antinociception elicited
by (1)-M1 because b-FNA has been used by several authors
to study the relationship between reduction in m-receptor
density and loss of agonist efficacy (Adams et al., 1990; Ran-
dich et al., 1993).
When dealing with opioid drugs, it is important to consider
their capability to induce respiratory depression (Lee et al.,
1993). Although tramadol has not caused clinically relevant
respiratory depression within the recommended dose range
(Houmes et al., 1992), no studies have been carried out to
examine the respiratory effect of its main metabolites. On the
basis of the above considerations, the respiratory effects of
(1)-M1 and (2)-M1 were also evaluated during this study.
Materials and Methods
Chemicals
The hydrochloride salts of (1)-M1, (2)-M1, and the ethoxy analog
of tramadol (used as an analytical internal standard) were kindly
supplied by Gru¨nenthal GmbH (Aachen, Germany). b-FNA was pur-
chased from Tocris Cookson Ltd. (Bristol, United Kingdom). All
reagents and solvents used were purchased from commercial sources
and were of analytical grade.
Animals
Male Sprague-Dawley rats weighing from 220 to 250 g were used
in the experiments. These animals were kept under laboratory stan-
dard conditions on a 12-h light/dark cycle, with light from 8:00 AM to
8:00 PM, in a temperature- (21–22°C) and humidity- (70%) controlled
room. They were acclimatized for a minimum of 4 days before exper-
iments were performed. Food (Standard Laboratory Rat, Mouse and
Hamster diets; Panlab, Barcelona, Spain) and water were available
ad libitum. The protocol of the study was approved by the Committee
on Animal Experimentation of the University of Basque Country.
Surgical Procedure
The day before the experiment, the rats were lightly anesthetized
with diethyl ether (Scharlau, Barcelona, Spain), and two polyethyl-
ene catheters (0.5 mm i.d., 11-cm-long; 0.3 mm i.d., 21-cm-long;
Vygon, Ecouen, France) were implanted in the left jugular vein and
right femoral artery for drug administration and blood sampling,
respectively. The catheters were filled with physiological saline so-
lution containing 1% heparin (50 I.U./ml; Roger Lab, Barcelona,
Spain) to prevent clotting. These catheters were tunneled under the
skin and exteriorized at the dorsal surface of the neck. Animals were
housed individually in cages with free access to water.
Drug Analysis
The levels of (1)-M1 and (2)-M1 in plasma were determined by
high-performance liquid chromatography with electrochemical de-
tection (Valle et al., 1999). Briefly, plasma samples were spiked with
10 ml of internal standard followed by 200 ml of ammonium hydrox-
ide. After the addition of 3 ml of ethyl acetate:N-hexane mixture
(40:60, v/v), samples were shaken on a Vortex mixer for 2 min and
centrifuged for 10 min at 3000 rpm. The organic phase was trans-
ferred to a 5-ml tube and evaporated down at vacuum in an Auto-
matic Environmental Speed Vac evaporator (AES 100; Savant, Bar-
celona, Spain). The dried residues were reconstituted in 100 ml of
deionized water, and an aliquot (50 ml) was injected into the chro-
matographic system.
The chromatographic system consisted of an HPLC 420 pump
(Kontron Instruments, Barcelona, Spain) fitted with a manual sam-
ple injector (model 7125; Rheodyne, Barcelona, Spain) equipped with
a 50-ml loop. Detection was performed with an ESA Coulochem
model 5200 (ESA, Bedford, MA) electrochemical detector consisting
of a model 5010 dual-electrode analytical cell (ESA) operating in the
oxidation screening mode, with the potential of the first electrode set
at 1610 mV and the second electrode at 1875 mV. Owing to the
extreme flow sensitivity of the electrochemical detector, a pulse
dampener was placed after the pump.
The analytical separation was performed by isocratic separation
at room temperature, using an Asahipack ODP-50 column (5-mm
particle size, 125- 3 4.0-mm i.d.; Hewlett Packard, Palo Alto, CA).
The mobile phase, consisting of 0.01 M borate buffer (pH 5 9) and
methanol (40:60, v/v), was filtered through a 0.22-mm membrane
filter (Millipore Corp., Barcelona, Spain) and degassed by sonication.
The flow rate was 0.7 ml/min; the mobile phase was recycled to
conserve the solvents. The limit of quantification when 100 ml of
plasma was used was 10 ng/ml; the signal showed linearity over the
range 10 to 4000 ng/ml. The intra- and interday coefficients of vari-
ation of the assay were 5.5 and 8.5%, respectively.
(1)-M1 Experiments
Respiratory Depression Studies. Respiratory depression was
studied in 20 rats randomly divided into five (n 5 4) groups. The
control group received a 10-min i.v. infusion of saline solution, and
each of the other groups received 10-min i.v. infusions of (1)-M1 with
10, 5, 2.5, or 2 mg/kg, respectively. Arterial blood samples (100 ml)
were collected in heparin-washed microtubes just before, during, and
after the infusion was stopped at the following times: 0, 10, 15, 20,
25, 30, 40, 55, 70, 85, 100, 130, 160, and 250 min. The pH, pO2, and
pCO2 levels were measured immediately by a blood gas analyzer
(AVL 990; AVL Biomedical Instruments, Graz, Austria).
pk and Antinociceptive Studies. Animals (n 5 33) were ran-
domly divided into seven groups, each receiving a saline solution
(three control groups) or a (1)-M1 infusion (groups I–IV) following
the schedule represented in Table 1. The choice of the infusion rate
TABLE 1
Experimental protocol (doses and length of infusions) performed during
the study describing the pharmacokinetic/pharmacodynamic
relationships of (1)-M1
Group n Length of the Infusion Dose
min mg/kg
I 6 10 2
II 6 10 0.7
III 6 60 2
IV 6 300 5.5
Control 3 10 0
Control 3 60 0
Control 3 300 0
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for group I was based on the results obtained from the respiratory
studies, and it included the highest dose avoiding changes in the
respiratory parameters. The infusion rates given to groups II, III,
and IV were calculated on the basis of the pk parameters obtained
from group I.
Antinociception was determined, and arterial blood samples (50/
100/200 ml) were withdrawn just before, during, and after the infu-
sions were stopped as follows: group I, 0, 2.5, 5, 7.5, 10, 12.5, 15, 25,
40, 55, 70, 100, 130, 190, and 250 min; group II, 0, 1, 2.5, 5, 7.5, 10,
11, 12, 15, 20, 30, 40, 55, 70, 85, and 100 min; group III, 0, 5, 15, 30,
45, 60, 62.5, 65, 70, 90, 105, 120, 150, 180, and 240 min; group IV, 0,
5, 15, 30, 45, 60, 90, 120, 180, 240, 300, 305, 315, 330, 345, 360, 390,
420, 480, 540, 600, and 660 min.
The maximal total blood volume sampled was 1.9 ml. The same
volume of extracted blood was reconstituted with heparinized phys-
iological saline solution. Blood samples were transferred to heparin-
ized tubes and were immediately centrifuged at 2500 rpm, 37°C, for
15 min to separate the plasma. Plasma was frozen and kept at 220°C
until analysis was performed.
The effects of blood sampling (50–200 ml) and the duration of the
infusion (10–300 min) on the antinociceptive effect were evaluated in
the three control groups receiving saline solution. Antinociception
was evaluated with the standard radiant heat tail-flick technique
(D’Amour and Smith, 1941). Tail-flick latency was measured auto-
matically with an Analgesic-Meter (Letica, Barcelona, Spain). The
intensity of heat was adjusted so that basal latencies were 2 to 3 s;
animals with higher baseline (.3–5 s) latencies were excluded from
the study. A maximum cut-off time of 10 s was used to avoid tissue
damage. Antinociception was expressed as a percentage of maximum
possible effect (%MPE) and was calculated using the following ex-
pression:
%MPE 5
Test Latency 2 Baseline Latency
Cut-off Time 2 Baseline Latency z 100
b-FNA Studies. Male Sprague-Dawley rats (n 5 12) were cannu-
lated as described above. Two hours later, when the rats had recov-
ered from the anesthesia, the antinociceptive baseline was mea-
sured, and a 10-mg/kg bolus dose of b-FNA was administered.
Twenty-four hours after b-FNA administration, the rats were ran-
domly divided into two groups receiving either 2 mg/kg (1)-M1 or
saline solution in a 10-min i.v. infusion. Just before, during, and
after the infusions were stopped, antinociception was determined,
and arterial blood samples were withdrawn at the following times: 0,
2.5, 5, 7.5, 10, 12.5, 15, 25, 40, 55, 70, 100, and 130 min. The same
volume of extracted blood was reconstituted with heparinized phys-
iological saline solution. Blood samples were transferred to heparin-
ized tubes and were immediately centrifuged at 2500 rpm, 37°C, for
15 min to separate the plasma. Plasma was frozen and kept at 220°C
until analysis was performed.
(2)-M1 Experiments
pk and Antinociceptive Studies. Animals (n 5 12) were ran-
domly divided into two groups (n 5 6). They received a 2- or 8-mg/kg
dose of (2)-M1, respectively, in a 10-min i.v. infusion. Antinocicep-
tion was determined as previously described for (1)-M1. Blood sam-
ples (50/100/200 ml) were collected at the start of the infusion and at
2.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 55, 70, 90, 120, and 150 min
thereafter. In the group receiving the higher dose, measurements
were also performed at 180, 240, and 300 min. Blood samples were
transferred to heparinized tubes and were immediately centrifuged
at 2500 rpm, 37°C, for 15 min to separate the plasma. Plasma was
frozen and kept at 220°C until analysis was performed.
Respiratory Depression Studies. Animals were randomly di-
vided into two groups (n 5 4) receiving 2 or 8 mg/kg of (2)-M1 in a
10-min i.v. infusion. Arterial blood samples (100 ml) were collected
following the same scheme as described above for (1)-M1; pH, pO2,
and pCO2 levels were determined.
Data Analysis
The time course of the plasma drug concentrations and antinoci-
ceptive effects was analyzed by population models using the first-
order and first-order conditional estimation methods implemented in
NONMEM (version V) software (Beal and Sheiner, 1992). This ap-
proach makes it possible to fit all data from all individuals simulta-
neously, describing both mean population tendencies and individual
profiles, and providing estimates of the interindividual variability
and residual (intraindividual) error. The residual error in the plasma
drug concentrations and antinociceptive effects was characterized by
proportional and additive error models, respectively:
Cij 5 Cpredij(1 1 «pkij)
Eij 5 Epredij 1 «pdij
where Cij and Eij are the jth observed plasma drug concentration and
the antinociceptive response for the ith individual, respectively.
Cpredij and Epredij are the jth model predicted plasma drug concen-
tration and the antinociceptive response for the ith individual, re-
spectively. epkij and epdij, the residual shift of the observations from
the model predictions, are random variables assumed to be symmet-
rically distributed around 0 with variances s2pk and s
2
pd, respec-
tively. Model predictions (Cpredij and Epredij) are based on the pk
and pd models selected (see below) and on the estimates of individual
parameters. For each parameter (P denotes an arbitrary pk or pd
parameter), the expression for the ith individual is:
Pi 5 Ppop z exp(hi)
where Ppop, the mean population estimate, and hi, the shift of the
parameter of the ith individual from the population mean, are ran-
dom variables assumed to be symmetrically distributed around 0
with diagonal variance-covariance matrix V with diagonal elements
(v1
2,. . . , vm
2). 1. . . m represent the pk or pd parameters to which
interindividual variability has been assigned. During the analysis,
Ppop, V, and s
2 were estimated.
pk Analysis. Multicompartmental pk models were used to de-
scribe the kinetics of both (1)-M1 and (2)-M1 in plasma. Distribu-
tion processes were assumed to be linear. In the case of (1)-M1, a
continuous increase in the plasma drug concentrations was seen
during the infusion in group IV, apparently indicating nonlinearity
in the elimination processes. This phenomenon was empirically mod-
eled as a time-dependent decrease in total plasma clearance (Cl):
Cl 5 Cl1 z exp(2Cl2 z time), where Cl1 and Cl2 represent mean popu-
lation parameters. Elimination of (2)-M1 was modeled as a linear
process.
pd Analysis. To model the time course of the response and to
overcome eventual model misspecifications occurring during the pk
analysis, the plasma drug concentration versus time profiles for each
animal were modeled nonparametrically with linear interpolation.
When the antinociceptive effect was plotted against the plasma
concentration in a time-ordered manner, counterclockwise hysteresis
was seen for all animals. This phenomenon suggests (among other
possible explanations) a time delay for (1)-M1 in plasma to equili-
brate with the biophase. Such a delay has been modeled by linking
plasma drug concentrations with effect site concentrations (Ce) by
means of a first-order rate constant (ke0; Sheiner et al., 1979). Linear,
Emax, and sigmoidal Emax models were explored to describe the pd
(effect versus Ce) relationship. This analysis shows that the pd
parameters of (1)-M1 depended on the length of the infusion, which
could be interpreted as a development of tolerance. Therefore, mod-
els accounting for tolerance development (Porchet et al., 1988; Ek-
blom et al., 1993; Mandema and Wada, 1995) were also fitted to the
data.
Model selection was based on the exploratory analysis of goodness-
of-fit plots performed with the Xpose package (Jonsson and Karlsson,
1999), the estimates of the parameters, and their confidence inter-
vals. The minimum value of the objective function provided by
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NONMEM was also used as a criterion for model selection. The
difference in the objective function between two hierarchical models
is approximately x2 distributed; P , .05 was used as the level of
significance. Results from the data analysis are presented as esti-
mated values and their coefficients of variation [c.v. (%)]. Estimates
of the interindividual and residual variability are expressed as c.v. (%).
Statistical Analysis
Results from the respiratory effects and antinociception for the
b-FNA experiments were represented as mean data with their cor-
responding standard deviations. Comparisons among groups were
made by one-way ANOVA followed by the Scheffe’s F test. Statistical
significance was set at P , .05.
Results
(1)-M1 Experiments
Respiratory Depression. (1)-M1, administered as an i.v.
infusion for 10 min, elicited a dose-dependent respiratory
depression characterized by a decrease in the arterial pH and
pO2 and an increase in arterial pCO2 levels (Fig. 1). Although
the pH levels decreased from a mean baseline value of 7.5 to
minimum values of 7.43, 7.39, 7.37, and 7.22 after the ad-
ministration of the 2-, 2.5-, 5-, and 10-mg/kg dose, respec-
tively, only the decrease observed after the highest dose was
found to be statistically significant (P , .05).
Time to maximum pH response depends also on the ad-
ministered dose. It ranged from 25 min in the 2.5-mg/kg dose
group to 40 to 55 min in the 10-mg/kg dose group. The time
for returning to baseline was approximately 100 min for the
2.5- and 5-mg/kg dose groups and 200 min for the highest
studied dose.
Similar patterns were seen for pO2 and pCO2 measures.
After the administration of the higher dose, pO2 levels
showed a statistically significant (P , .05) decrease of 32 mm
Hg with respect to baseline, and pCO2 levels showed a sta-
tistically significant increase (P , .05) of 32 mm Hg with
respect to baseline. Time to peak response increased again
with the administered dose, and no rebound effects were
found. pCO2 returned to baseline 120 min after the admin-
istration of the highest dose, whereas for pO2, the time to
baseline was ;250 min (see Fig. 1).
pk. The mean observed plasma concentrations of (1)-M1
versus time profiles for groups I to IV are represented in Fig.
2. Maximum mean observed plasma drug concentrations
were 639.2 6 299.6, 187.54 6 79.5, 208.62 6 36.7, and
261.4 6 37.2 ng/ml for groups I to IV, respectively.
Figure 2 also shows the time course of the mean population
predictions. Drug disposition was best described by a two-
compartmental model. Describing the elimination of (1)-M1
as a function dependent on the time after the start of the
infusion significantly improved the fit (P , .01). Estimates of
fixed and random parameters are listed in Table 2. No co-
variate effects of the total administered dose or the length of
infusion were found. Interindividual variability could only be
estimated in total clearance and initial volume of distribu-
tion, resulting in 23 and 55%, respectively.
pk/pd Analysis of the Antinociceptive Effect. When
saline was administered in infusions of 10, 60, or 300 min, no
antinociception was observed. The %MPE ranged between 0
and 29%. Baseline antinociceptive measurements did not
differ statistically (P . .05) between control and drug-treated
groups.
The time course of the antinociception in groups I to IV is
shown in Fig. 3. The mean peak observed effect in groups I
and III was 100%. For groups II and IV, the maximum
observed effect was 42.9 and 90.5%, respectively. Time to
peak was 15 min for groups I and II. Time to peak for groups
III and IV occurred at the end of the infusion (60 and 300
min, respectively).
Antinociception versus effect site concentrations was best
Fig. 1. Time course of arterial pH (upper panel), pCO2 (middle panel),
and pO2 (lower panel) after the administration of saline (f), 10 (F), 5 (E),
or 2.5 () mg/kg (1)-M1 in 10-min i.v. infusions. Points represent the
mean data and vertical lines represent the standard deviations.
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modeled by a linear pharmacodynamic model. A significantly
(P , .001) better fit was obtained when different typical
values for ke0 and slope were estimated for each group, com-
pared with the model using the same typical value for ke0 and
slope in all groups. Table 3 lists the estimates of ke0 and slope
for each of the groups. There is a clear tendency for ke0 to
increase and for slope to decrease with the length of the
infusions. Although different models allowing for tolerance
development were fitted to the data (see Materials and Meth-
ods), none of them gave adequate predictions or reasonable
parameter estimates.
b-FNA Experiments. The pretreatment with 10 mg/kg
b-FNA did not alter the baseline antinociception; however, as
is represented in Fig. 4, b-FNA pretreatment antagonized
completely the antinociceptive effect of the 2-mg/kg dose of
(1)-M1 administered in a 10-min i.v. infusion, the maximum
mean observed effect being 11.7%. pk parameters of (1)-M1
in rats pretreated with b-FNA did not differ (P . .05) from
those obtained for groups I to IV (data not shown).
(2)-M1 Experiments
Figure 5 shows the pk profiles of (2)-M1 after the admin-
istration of a 2- or 8-mg/kg dose in 10-min i.v. infusions. The
disposition of (2)-M1 in plasma was best described by a
two-compartmental model. pk behavior was different be-
tween the two administered dose groups. Differences affected
initial volume of distribution and total plasma clearance.
Table 4 lists the estimates of the pk parameters.
Antinociceptive and respiratory measurements were re-
corded during and after the infusion of (2)-M1. However, no
significant changes (P . .05) from baseline were detected in
either effect (data not shown).
Discussion
Tramadol is a centrally acting analgesic drug with several
potentially complicating pk/pd factors that could make the
interpretation of the time course of antinociception difficult.
In fact, to our knowledge nothing describing its pk/pd rela-
tionships has been published. These factors include: 1) Ki-
netic disequilibrium between plasma and biophase (central
nervous system). Several authors have reported delays be-
tween plasma and the effect compartment for several opioid
drugs, such as morphine (Ekblom et al., 1993), methadone
(Garrido et al., 1999), and alfentanyl (Mandema and Wada,
1995). 2) Tolerance development. This phenomenon has also
been observed and quantified for opioid drugs such as mor-
phine (Ouellet and Pollack, 1995, Gårdmark et al., 1993) and
alfentanyl (Mandema and Wada, 1995). 3) Pharmacodynamic
interactions. Tramadol is administered as a racemic mixture
of two active enantiomers (Raffa et al., 1993), and, conse-
quently, interactions are expected to be present. In addition,
each of the enantiomers forms active metabolites (Paar et al.,
1992) that could modify these interactions or make them
more complex.
The aim of this work is the analysis of the pk/pd relation-
ships of the two main active metabolites, (1)-M1 and (2)-M1,
because there are some indications that suggest they might
play a significant role in the analgesic effect of tramadol
(Raffa and Friderichs, 1996). Both metabolites were admin-
Fig. 2. Time course of the plasma concentrations of (1)-M1. Points
represent mean observed data for groups I (E), II (F), III (), and IV ().
Lines represent mean population model predictions for groups I (— —), II
(-z-), III (- - -), and IV (- -). Standard deviations have been omitted for
clarity.
TABLE 2
Pharmacokinetic parameter estimates of (1)-M1
Estimates of interindividual variability are expressed as c.v. (%). Precision of the
estimates is expressed as relative standard error in parentheses. Relative standard
error is standard error divided by the parameter estimate.
Parameter Estimate IIV
Vc (l) 0.100 (0.33) 55 (0.65)
VSS (l) 0.781 (0.08) NE
Cld (l/min) 0.0563 (0.12) NE
Cl 5 Cl1 z exp(2Cl2 z time) (l/min) Cl1 5 0.035 (0.07) 23 (0.42)
Cl2 5 0.0023 (0.17)
Vc, initial volume of distribution; VSS, apparent volume of distribution at steady
state; Cld, intercompartmental clearance; IIV, interindividual variability; NE, not
estimated in the model.
Fig. 3. Time course of %MPE after (1)-M1 administration. Points repre-
sent mean observed data for groups I (E), II (F), III (), and IV (). Lines
represent mean population model predictions for groups I (— —), II (-z-),
III (- - -), and IV (- -). Standard deviations have been omitted for clarity.
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istered separately because this type of design offers the ad-
vantage of obtaining direct information about the pk and pd
properties of the metabolites, and this design has been pre-
viously used for other drugs with active metabolites like
midazolam (Mandema et al., 1992).
(1)-M1 Experiments. (1)-M1 was administered at differ-
ent rates in i.v. infusions of different lengths. This procedure
is similar to that used by Gårdmark et al. (1993) to evaluate
the pk/pd properties of morphine. The tail-flick test has been
shown to be appropriate for characterizing in vivo responses
associated with the interaction of agonists with the m-recep-
tor, as has been reported for buprenorphine (Ohtani et al.,
1995), methadone (Garrido et al., 1999), and morphine (Ouel-
let and Pollack, 1997).
The doses given during the pk/pd analysis of the antinoci-
ceptive response were chosen on the basis of the results of the
respiratory depression experiments and were those with no
associated respiratory effects. It was found that doses lower
than 2 mg/kg given in a 10-min i.v. infusion were unlikely to
have respiratory effects. Doses higher than 2.5 mg/kg, ad-
ministered by short i.v. infusion (10 min), produced dose-
dependent respiratory depression characterized by a de-
crease in pH and pO2 levels and an increase in pCO2 levels.
Comparison of the results of this study with data from other
opioids showed that 10 mg/kg (1)-M1 administered in 10-min
i.v. infusion elicits an alteration in the respiratory parame-
ters similar to 7.5 mg/kg methadone administered as an i.p.
injection (White and Zagon, 1979) or to 3 mg/kg norbuprenor-
phine (active metabolite of buprenorhine) administered as an
i.v. bolus (Ohtani et al., 1997).
(1)-M1 kinetics in plasma was best described with a two-
compartmental model. The distribution phase was fast (dis-
tribution half-life 5 1.2 min) and linear over the dose range
studied. However, clearance showed a slight decrease in time
after the start of the infusion. A similar pattern has been
described previously for other opioids administered in long
infusions. Ekblom et al. (1993) and Gårdmark et al. (1993)
observed that total plasma clearance of morphine decreased
after long infusions when compared with those estimated
from short infusions or bolus data. In our study, because
maximum plasma drug concentrations were similar for
groups II, III, and IV, the decrease in clearance could not be
TABLE 3
Pharmacodynamic parameter estimates of (1)-M1
Estimates of interindividual variability are expressed as c.v. (%). Precision of the estimates is expressed as relative standard error in parenthesis. Relative standard error
is standard error divided by the parameter estimate.
Group I Group II Group III Group IV IIV
ke0 (1/min) 0.03 (0.10) 0.02 (0.50) 0.05 (0.56) 0.28 (1.40) 0.13 (0.69)
Slope (% ml/ng) 0.53 (0.075) 0.58 (0.41) 0.41 (0.12) 0.33 (0.18) 0.68 (0.05)
ke0, first-order rate constant of equilibrium between plasma and effect compartment; IIV, interindividual variability.
Fig. 4. Time course of the antinociceptive effect after saline administra-
tion (E), 2 mg/kg (1)-M1 in 10-min i.v. infusion (F), and 2 mg/kg (1)-M1
in 10-min i.v. infusion in the b-FNA pretreated group (). Points repre-
sent mean observed data and vertical lines represent standard devia-
tions.
Fig. 5. Time course of the plasma concentrations of (2)-M1. Points
represent mean observed data with standard deviations for the 2- (F) and
8-mg/kg (E) dose groups. Lines represent mean population model predic-
tions: solid (2 mg/kg) and dashed (8 mg/kg).
TABLE 4
Pharmacokinetic parameter estimates of (2)-M1
Estimates of interindividual variability are expressed as c.v. (%). Precision of the
estimates is expressed as relative standard error in parentheses. Relative standard
error is standard error divided by the parameter estimate.
Parameter Estimate IIV
Vc(1) (l) 0.255 (0.23) 0.58 (0.67)
Vc(2) (l) 0.05 (0.18)
VSS (l) 0.72 (0.07) NE
Cld (l/min) 0.036 (0.14) NE
Cl(1) (l/min) 0.0395 (0.07) 0.84 (0.47)
Cl(2) (l/min) 0.0156 (0.05)
(1) and (2) refer to 2- and 8-mg/kg doses, respectively. Vc, initial volume of
distribution; VSS, apparent volume of distribution at steady state; Cld, intercompart-
mental clearance; IIV, interindividual variability; NE, not estimated in the model.
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explained by a concentration-dependent process. This finding
could be related to the fact that there is a possibility for
higher respiratory effects during the 300-min infusion than
during the 10- or 60-min infusions; however, the effect of
respiratory depression on the elimination of (1)-M1 has not
been established yet.
The 20-min estimate of the mean population terminal half-
life obtained in this study differs from the 4.23-h estimate
reported previously by Takacs (1995). Because the adminis-
tered drug was tramadol in that study, those differences
suggest that the rate of elimination of (1)-M1 is limited by its
rate of formation from the parent compound.
The pk/pd analysis of the antinociceptive effect suggests
tolerance development because the estimates of ke0 and slope
increase and decrease, respectively, with the length of the
infusion (Table 3). In addition, for the two 10-min infusions,
the one associated with higher plasma drug concentrations
(group I) corresponds to a higher ke0 and lower slope values.
These results indicate that development of tolerance depends
on total drug exposure. Although a priori, our experimental
design was appropriate to account for development of toler-
ance, owing to the fact that during the longer infusion plasma
drug concentrations were continuously increasing, such a
phenomenon could not be adequately quantified.
The value of mean population estimates of ke0 (0.03/min)
for the 10-min lowest dose infusion group (no, or minor tol-
erance development) was lower than the value estimated for
methadone (1.44/min; Garrido et al., 1999), similar to that
estimated for morphine (0.073/min; Ouellet and Pollack,
1995), and higher than those described for morphine-6-gluc-
uronide (0.005/min; Gårdmark and Hammarlund-Udenaes,
1998) and morphine (0.02/min; Gårdmark et al., 1993). These
differences could be explained by differences in liposolubility
between the drugs (Dutta et al., 1998).
Recently, Grond et al. (1999) determined the plasma con-
centrations of the enantiomers of tramadol and M1 metabo-
lite following an i.v. bolus dose of 200 mg and demand doses
of 20 mg. It was found that the mean (1)-M1 plasma drug
concentration before demand was 57 ng/ml, so (1)-M1
plasma concentrations were probably well above 57 ng/ml at
times near drug administration. Taking into account that our
experiments showed that (1)-M1 steady-state plasma drug
concentrations of 200 ng/ml elicit near maximal antinocicep-
tion, (1)-M1 could be expected to have a role in the analgesic
effect of tramadol. However, additional studies are required
to characterize the nature of the tramadol/(1)-M1 interaction
in humans.
b-FNA is a m-selective irreversible antagonist that pro-
duces a long-lasting antagonism of several behavioral effects
of m-agonist. However, it does not antagonize the effects of
drugs acting at k- or d-opioid receptors (Pitts et al., 1998).
Generally, the antagonism of b-FNA evidences the fact that
a given behavioral effect of a drug involves actions on m-opi-
oid receptors. The insurmountable antagonism of b-FNA on
the antinociceptive effect elicited by (1)-M1 supports the
results from in vitro studies where (1)-M1 showed a moder-
ate affinity for m-opioid receptors: Ki 5 153 nM (Lai et al.,
1996), and shows that the behavior of (1)-M1 in the antino-
ciceptive test is mediated by m-opioid receptors. Similar re-
sults were reported by Randich et al. (1993) for a 1-mg/kg i.v.
dose of morphine given 24 h after pretreatment with a 10-
mg/kg i.v. bolus of b-FNA in rats, using the tail-flick reflex
test.
(2)-M1 Experiments. The kinetics of (2)-M1 was best
described using a two-compartmental model. The 4-fold dif-
ferences found in total clearance and initial volume of distri-
bution between the two doses used in the current study could
explain dose-dependent distribution and elimination kinet-
ics. The pk estimates obtained from the analysis of the lower-
dose group were similar to those obtained during the pk
analysis of the (1)-M1 data, suggesting that, after adminis-
tration of low doses, both enantiomers have similar kinetics.
(2)-M1 presents a very low affinity for opioid receptors (Lai
et al., 1996), its main action being due to the inhibition of the
NA uptake (Driessen et al., 1993). As was expected on the
basis of the in vitro properties of (2)-M1, no antinociceptive
effect in the tail-flick test or respiratory depression was ob-
served after the administration of this compound in this
study, despite the high administered doses. Several in vivo
studies have reported an important contribution by the non-
opiate component of tramadol in its antinociception because
a peripheral administration of the alpha2-adrenergic antag-
onists, such as yohimbine, blocked partially its antinocicep-
tive effect (Raffa et al., 1995). In addition, the potentiation of
opioid analgesia by NA uptake blockers and a2-agonists is
documented in clinical and preclinical findings, although
there is no consensus about the intrinsic antinociceptive ef-
fect of these compounds on their own (Sevcik et al., 1993;
Codd et al., 1995). In this case, the (2)-M1, a compound with
the property to inhibit NA uptake, did not induce either
antinociceptive effect in the tail-flick test or adverse effects
such as respiratory depression.
In conclusion, this study represents the first pk/pd analysis
of the two main active metabolites of tramadol. The pharma-
cokinetics of both compounds can be considered similar and
is well described with multicompartmental models. Antino-
ciceptive response elicited by (1)-M1 could be described by
standard pk/pd models and was mediated by m-opioid recep-
tor activation. In our results we found evidence for the de-
velopment of tolerance. Respiratory effects were observed at
higher doses than the ones given the maximum antinocicep-
tion. (2)-M1 showed neither antinociception in the tail-flick
test nor respiratory effects. Further studies are required to
account for the interaction of both compounds given simul-
taneously.
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